| Primary |
| Cystic Fibrosis |
45.6% |
| Product Used For Unknown Indication |
18.8% |
| Pseudomonas Infection |
15.2% |
| Cystic Fibrosis Lung |
5.0% |
| Bronchiectasis |
1.9% |
| Bacterial Disease Carrier |
1.7% |
| Infective Pulmonary Exacerbation Of Cystic Fibrosis |
1.7% |
| Gastrooesophageal Reflux Disease |
1.2% |
| Pancreatic Insufficiency |
1.2% |
| Bronchial Hyperreactivity |
1.0% |
| Chronic Obstructive Pulmonary Disease |
1.0% |
| Lung Disorder |
1.0% |
| Bronchospasm |
0.8% |
| Medical Diet |
0.8% |
| Pneumonia Pseudomonal |
0.8% |
| Convulsion |
0.6% |
| Malabsorption |
0.6% |
| Pain |
0.6% |
| Bronchitis |
0.4% |
| Bronchopneumonia |
0.4% |
|
| Death |
46.9% |
| Respiratory Failure |
20.5% |
| Lung Disorder |
4.4% |
| Cystic Fibrosis |
4.0% |
| Haemoptysis |
2.9% |
| Infective Pulmonary Exacerbation Of Cystic Fibrosis |
2.9% |
| Bronchitis |
1.8% |
| Cardiopulmonary Failure |
1.8% |
| Sepsis |
1.8% |
| Dyspnoea |
1.5% |
| Nausea |
1.5% |
| Pulmonary Function Test Decreased |
1.5% |
| Urticaria |
1.5% |
| Joint Swelling |
1.1% |
| Pneumonia |
1.1% |
| Pulmonary Embolism |
1.1% |
| Pyrexia |
1.1% |
| Rash |
1.1% |
| Bronchospasm |
0.7% |
| Cardio-respiratory Arrest |
0.7% |
|
| Secondary |
| Cystic Fibrosis |
36.0% |
| Pseudomonas Infection |
30.4% |
| Product Used For Unknown Indication |
5.6% |
| Bacterial Disease Carrier |
4.7% |
| Bronchiectasis |
4.7% |
| Cystic Fibrosis Lung |
3.7% |
| Infective Pulmonary Exacerbation Of Cystic Fibrosis |
1.9% |
| Chronic Obstructive Pulmonary Disease |
1.4% |
| Gastrooesophageal Reflux Disease |
1.4% |
| Staphylococcal Infection |
1.4% |
| Bronchospasm |
0.9% |
| Lung Disorder |
0.9% |
| Metabolic Disorder |
0.9% |
| Oedema |
0.9% |
| Pain |
0.9% |
| Pancreatic Insufficiency |
0.9% |
| Pneumonia Pseudomonal |
0.9% |
| Pulmonary Function Test Decreased |
0.9% |
| Stenotrophomonas Infection |
0.9% |
| Anaemia |
0.5% |
|
| Respiratory Failure |
39.5% |
| Haemoptysis |
8.6% |
| Cystic Fibrosis |
6.2% |
| Death |
6.2% |
| Lung Disorder |
6.2% |
| Cardiopulmonary Failure |
4.9% |
| Infective Pulmonary Exacerbation Of Cystic Fibrosis |
3.7% |
| Cardio-respiratory Arrest |
2.5% |
| Fatigue |
2.5% |
| Hypoxia |
2.5% |
| Pseudomonas Infection |
2.5% |
| Renal Failure Acute |
2.5% |
| Upper Respiratory Tract Congestion |
2.5% |
| Vomiting |
2.5% |
| Acute Respiratory Failure |
1.2% |
| Bacterial Sepsis |
1.2% |
| Bronchospasm |
1.2% |
| Constipation |
1.2% |
| Drug Ineffective |
1.2% |
| Dyspnoea |
1.2% |
|
| Concomitant |
| Cystic Fibrosis |
61.5% |
| Pseudomonas Infection |
5.2% |
| Asthma |
4.2% |
| Bronchitis |
4.2% |
| Product Used For Unknown Indication |
4.2% |
| Pancreatic Insufficiency |
3.1% |
| Cough |
2.1% |
| Diabetes Mellitus |
2.1% |
| Dyspnoea |
2.1% |
| Bronchopulmonary Aspergillosis Allergic |
1.0% |
| Contraception |
1.0% |
| Cystic Fibrosis Lung |
1.0% |
| Forced Expiratory Volume |
1.0% |
| Gastrooesophageal Reflux Disease |
1.0% |
| Hepatitis C |
1.0% |
| Hereditary Spherocytosis |
1.0% |
| Hypersensitivity |
1.0% |
| Infective Pulmonary Exacerbation Of Cystic Fibrosis |
1.0% |
| Osteoporosis |
1.0% |
| Pain |
1.0% |
|
| Infective Pulmonary Exacerbation Of Cystic Fibrosis |
16.3% |
| Staphylococcal Infection |
9.3% |
| Lung Infection |
7.0% |
| Malaise |
7.0% |
| Constipation |
4.7% |
| Disease Complication |
4.7% |
| Infection |
4.7% |
| Intestinal Malrotation |
4.7% |
| Pneumonia |
4.7% |
| Pulmonary Function Test Decreased |
4.7% |
| Sinus Congestion |
4.7% |
| Sinus Disorder |
4.7% |
| Upper Respiratory Tract Infection |
4.7% |
| Weight Decreased |
4.7% |
| Asthenia |
2.3% |
| Blood Disorder |
2.3% |
| Bronchitis |
2.3% |
| Device Expulsion |
2.3% |
| Distal Ileal Obstruction Syndrome |
2.3% |
| Ear Infection |
2.3% |
|
